EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Metastatic response and short-term survival outcomes in patients with stage IV rectal cancer treated with curative intent in the era of Total Neoadjuvant Therapy

T R Fitzsimmons, Z Bunjo, E L Neo, A Badiei, M Penniment, S Selva-Nayagam, T Sammour

European Journal of Surgical Oncology · 2026-04 · 52 (4) · 111464

DOI: 10.1016/j.ejso.2026.111464 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Surgical Oncology, 2026-04. Verfasst von T R Fitzsimmons und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical Specialties, Adelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, South Australi…. Hauptthemen laut MEDLINE: Rectal Neoplasms, Neoadjuvant Therapy, Antineoplastic Combined Chemotherapy Protocols, Adenocarcinoma. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Council South Australia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: While patients with stage IV rectal cancer treated with curative intent have a high risk of distant failure, the benefits of delivering systemic treatment within a TNT setting remain unexplored. We describe the short-term outcomes of stage IV rectal cancer patients treated with curative intent using a personalised TNT (pTNT) approach. METHODS: All rectal cancer patients with resectable metastases were treated with pTNT over a 5-year period and included in a prospective database. The primary outcome of this cohort analysis was grade of metastatic response to pTNT. A subset analysis was performed for patients with a minimum of 36 months follow-up and 3-year progression free and overall survival rates were determined. RESULTS: Of 141 patients diagnosed with stage IV rectal cancer during the study period, 62 were treated with curative intent using a pTNT protocol. On initial restaging, 38.7% demonstrated a complete metastatic response and 33.9% exhibiting partial response. The remaining 27.4% progressed on treatment. A complete clinical response (cCR) in the primary rectal tumour was seen in 32.3% of patients. In the subset analysis of 39 patients with a minimum follow-up of 36 months, the 3-year progression free survival rate was 30.8% (median 20.19 months, 95%CI 12.924-27.456) and 3-year overall survival rate of 61.5% (median 44.52 months, 95%CI 31.527-57.513). CONCLUSION: A pTNT approach to stage IV rectal cancer with curative intent resulted in favourable metastatic and primary tumour response in most patients. These results provide support for pTNT to be given consideration as a primary treatment option for these patients, pending longer term survival data.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rectal NeoplasmsNeoadjuvant TherapyAntineoplastic Combined Chemotherapy ProtocolsAdenocarcinomaLiver NeoplasmsHumansNeoplasm StagingFemaleMaleMiddle AgedAgedSurvival RateAdultProgression-Free Survival

Stichwörter der Autor:innen

Metastatic rectal cancerRectal cancerTotal neoadjuvant therapy

Autor:innen und Institutionen

  • Department of Surgical Specialties, Adelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia; Colorectal Surgical Unit, Royal Adelaide Hospital, Adela…
  • Department of Hepatobiliary Surgery, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
  • Department of Thoracic Medicine, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
  • Department of Radiation Oncology, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
  • Department of Medical Oncology, Royal Adelaide Hospital, Adelaide, South Australia, Australia.

Förderung

  • Cancer Council South Australia

Zitieren

APA

Fitzsimmons, T. R., Bunjo, Z., Neo, E. L., Badiei, A., Penniment, M., Selva-Nayagam, S., & Sammour, T. (2026). Metastatic response and short-term survival outcomes in patients with stage IV rectal cancer treated with curative intent in the era of Total Neoadjuvant Therapy. European Journal of Surgical Oncology, 52(4), 111464. https://doi.org/10.1016/j.ejso.2026.111464

Vancouver

Fitzsimmons TR, Bunjo Z, Neo EL, Badiei A, Penniment M, Selva-Nayagam S, et al. Metastatic response and short-term survival outcomes in patients with stage IV rectal cancer treated with curative intent in the era of Total Neoadjuvant Therapy. European Journal of Surgical Oncology. 2026;52(4):111464. doi:10.1016/j.ejso.2026.111464

BibTeX
@article{Fitzsimmons2026,
  author = {Fitzsimmons, T R and Bunjo, Z and Neo, E L and Badiei, A and Penniment, M and Selva-Nayagam, S and Sammour, T},
  title = {Metastatic response and short-term survival outcomes in patients with stage IV rectal cancer treated with curative intent in the era of Total Neoadjuvant Therapy},
  journal = {European Journal of Surgical Oncology},
  year = {2026},
  volume = {52},
  number = {4},
  pages = {111464},
  doi = {10.1016/j.ejso.2026.111464}
}
Kostenlos starten →